Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT04214652 Completed - Acne Vulgaris Clinical Trials

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Start date: January 27, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.

NCT ID: NCT04214639 Completed - Acne Vulgaris Clinical Trials

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Start date: January 17, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12.

NCT ID: NCT04214483 Recruiting - Acne Vulgaris Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Acne

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04213638 Recruiting - Acne Vulgaris Clinical Trials

Trial of Single Microneedle Radiofrequency for Moderate‐to‐Severe Acne Vulgaris

Start date: November 15, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to testify the efficacy of treating moderate‐to‐severe acne vulgaris with Single Microneedle Radiofrequency, and provide evidence for the hypothesis that "whether Single Microneedle Radiofrequency therapy could be an alternative to photodynamic therapy for moderate to severe acne vulgaris."

NCT ID: NCT04206631 Completed - Acne Vulgaris Clinical Trials

Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris

Start date: April 1, 2015
Phase: Phase 1
Study type: Interventional

The objective of the study was to evaluate the effectiveness of comedone extraction compared to oral antibiotics as the main therapy of moderate acne vulgaris (MAV); and to determine the expression of HIF-1 alpha by examining the immunohistochemistry and ELISA as a sign of hypoxia/anoxia in MAV lesion. This was a randomized, placebo-controlled clinical trial that was performed in 2015 at three different dermatology clinics in Indonesia, Cipto Mangunkusumo Hospital Jakarta, Gatot Soebroto Army Hospital Jakarta, and PT. Mattel Indonesia, Cikarang. One hundred and twenty eight subjects with moderate acne vulgaris were recruited and randomized to receive either oral doxycycline or comedone extraction for six weeks. Subjects who had acne lesion and the back area were offered skin lesion biopsy to evaluate immunohistochemistry and ELISA before administration of medication. The main outcome was total reduction of inflammatory and non inflammatory lesions, evaluated every two weeks.

NCT ID: NCT04167982 Recruiting - Acne Clinical Trials

Efficacy and Safety of Painless 5-aminolevulinic Acid Photodynamic Therapy for Moderate and Severe Acne Vulgaris

Start date: March 28, 2020
Phase: N/A
Study type: Interventional

This study is being done to compare a new, continuous illumination and short Incubation time regimen of 5-aminolevulinic acid photodynamic therapy (painless ALA- PDT) to low-dose and conventional dose of oral isotretinoin for treatment of moderate or severe acne vulgaris. The hypothesis is that the painless ALA- PDT will be equally or more efficacious as oral isotretinoin, and taking effect more quickly with less adverse effect.

NCT ID: NCT04163263 Completed - Clinical trials for Moderate to Severe Acne Vulgaris

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Start date: November 4, 2019
Phase: Phase 1
Study type: Interventional

This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application

NCT ID: NCT04156815 Completed - Acne Vulgaris Clinical Trials

Treatment of Acne Vulgaris Using NAFL in Combination With Isotretinoin and Pricking Blood Therapy

Start date: July 5, 2018
Phase: N/A
Study type: Interventional

BACKGROUND Isotretinoin remains one of the first line medications for moderate-to-severe acne vulgaris (AV) but its side effect is a major concern for Asian patients. OBJECTIVE Investigators aimed to evaluate the efficacy and safety of the 1,565 nm non-ablative fractional laser (NAFL) in combination with isotretinoin and pricking blood therapy (PBT) for treatment of AV. METHODS A retrospective analysis of 60 patients with moderate-to-severe AV was performed. Four groups (n=15) were evaluated: 1,565nm NAFL alone, oral isotretinoin alone, double therapy (NAFL + isotretinoin) and triple therapy (NAFL + isotretinoin + PBT).

NCT ID: NCT04134273 Completed - Acne Vulgaris Clinical Trials

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

Start date: March 20, 2019
Phase: Phase 1
Study type: Interventional

This study is to evaluate the therapeutic equivalence and safety of Taro Product to RLD in the treatment of acne vulgaris.

NCT ID: NCT04118296 Completed - Acne Vulgaris Clinical Trials

Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream

Start date: October 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study was conducted to see whether there was a decrease in the degree of acne vulgaris / pimple, to find out what proportion of respondents experienced a decrease in severity and who did not experience a decrease in the severity of acne vulgaris after the use of an anti-acne cream combination containing active ingredients such as; Tretinoin 0.05% (derivatives of Vitamin A), Clindamycin 5% (antibiotics), and Dexamethasone 0.05% (anti-inflammatory) for 1 month of use.